- Home
- PETS vs INKT Comparison
PETS vs INKT Comparison
Compare PETS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | INKT |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 70.6M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETS | INKT |
|---|---|---|
| Price | $2.13 | $11.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 59.4K | 23.9K |
| Earning Date | 06-09-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $6.80 |
| 52 Week High | $4.32 | $76.00 |
Technical Indicators
Market Signals| Indicator | PETS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 48.35 |
| Support Level | N/A | $10.79 |
| Resistance Level | $2.44 | $12.40 |
| Average True Range (ATR) | 0.08 | 0.75 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 6.21 | 54.26 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.